Peptide Decoding
New?New to peptides?Start here →
Decoding

Galinpepimut-S (GPS)_Dosage, benefits & legal status

Also known as GPS, galinpepimut, WT1 analog peptide vaccine, WT-1 vax

Published November 19, 2026

A four-peptide leukemia vaccine built on a single engineered amino acid swap.

Keep leukemia from returningFour-peptide WT1 vaccine (injected with adjuvants)Investigational
Dose800 mcg total, 200 mcg of each of the four peptides (published trials)
FrequencySix doses every two weeks, with monthly doses after (trial schedules)
RouteUnder the skin (subcutaneous), emulsified with Montanide, alongside GM-CSF
StatusInvestigational
CycledSix doses every two weeks, then monthly doses where the protocol allows

See how this dose compares across the library →

01

What is Galinpepimut-S (GPS)?

Plain language first. The technical label stays, but it never stands alone.

Overview

Four leukemia-protein fragments injected together to train the immune system to spot the cancer.

The technical version

A tetravalent WT1-derived peptide vaccine, two native and two heteroclitic sequences, emulsified in Montanide and given subcutaneously with GM-CSF as maintenance immunotherapy.

What it's used for

An investigational maintenance vaccine for acute myeloid leukemia in remission, given to people who cannot have a transplant.

02

How does Galinpepimut-S (GPS) work?

What it does in the body, and where.

WT1 is a protein that healthy adult tissue barely makes and that many leukemias and solid tumors make a great deal of. That gap is what makes it a target. The problem is that the immune system is trained not to attack its own proteins, so a vaccine made of native WT1 fragments tends to do very little. Galinpepimut-S gets around that with a single deliberate mutation.

  1. 01
    Two of the four peptides are native, two are not
    The 331 and 427 long peptides reproduce the WT1 sequence exactly. The short WT1-A1 peptide and the long 122A1 peptide each carry one changed residue, arginine replaced by tyrosine at position 126. The sponsor describes the mixture as two native and two synthetic sequences.
  2. 02
    The mutation makes the peptide stick better
    Changing that one residue improves how the peptide sits in the groove of an HLA class I molecule, which is the display case a cell uses to show fragments to killer T cells. A peptide that is displayed more stably provokes a stronger response. This is called a heteroclitic peptide.
  3. 03
    The trick only works if the response still finds the real thing
    A stronger response to a mutated peptide is useless unless those T cells also recognize the unmutated protein on a tumor cell. The originating work reported exactly that: T cells raised against the synthetic peptides cross-reacted with the native WT1 sequence and killed matched leukemia blasts. That cross-reaction is the whole design.
  4. 04
    Two arms of the immune system, not one
    The short peptide is sized for killer T cells on HLA class I. The two long peptides are sized for helper T cells on HLA class II. The 122A1 long peptide contains the short one inside it, so it can feed both. That is why no particular tissue type is required for entry, unlike the HER2 vaccine nelipepimut-S.
  5. 05
    The adjuvants are not optional
    Montanide emulsifies the peptides so they stay at the injection site and keep provoking the local immune system, and GM-CSF given before and on the day draws antigen-presenting cells to that spot. No published protocol gives the peptides alone, which means the trial result belongs to the three-part regimen.
Pathway
THE PEPTIDE
Galinpepimut-S (GPS)
ACTS ON
WT1, shown to both helper and killer T cells across several tissue types
RESULT
Median overall survival 24.0 months against 14.7 in the phase 3
RESULT
Hazard ratio 0.59, two-sided P equals 0.035, on 80 deaths

A schematic of the compound's mechanism, not a diagnostic image.

03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Acute myeloid leukemia in second or later remission, the phase 3 indicationtrial-protocol
  • Malignant pleural mesothelioma after multimodality therapy, a randomized phase 2peer-reviewed-human
  • Multiple myeloma after autologous stem cell transplantation, a registered trialtrial-protocol
  • Combination with pembrolizumab in selected advanced cancerstrial-protocol

The published record

Research index

6

Papers about Galinpepimut-S (GPS) · this compound only

Searched: Galinpepimut-S, galinpepimut.

Left out: GPS (three letters with many unrelated meanings); WT1 (the protein the peptides come from, with a very large literature of its own); YMFPNAPYL (one of the four peptide sequences, which is used in other vaccines too); RMFPNAPYL (the unmodified version of that sequence, used across the whole field); SGQAYMFPNAPYLPSCLES (another of the four sequences, with the same problem); RSDELVRHHNMHQRNMTKL (a sequence taken unchanged from the target protein); PGCNKRYFKLSHLQMHSRKHTG (another sequence taken unchanged from the target protein); WT1-A1 (the name of one component peptide, not of the product); 122A1 (the name of another component, which also matches unrelated codes); heteroclitic (a peptide design term used across many unrelated vaccines); Montanide (one of the two adjuvants given with it, used in many unrelated vaccines); GM-CSF (the other adjuvant, with a very large literature of its own); sargramostim (that adjuvant's drug name); REGAL (the phase 3 trial's name, which is also an ordinary word); nelipepimut-S (a different peptide cancer vaccine, already covered on its own page); rindopepimut (another peptide cancer vaccine, already covered on its own page); SLS009 (a different compound from the same company); SLS-001 (a code seen in secondary write-ups that could not be confirmed for this product).

11 papers tagged human · 3 not reviews or lab · 2 clinical trial publications

7 registered trials · 4 with posted results

Furthest stage reached: Phase 3, under way

Compare this against the whole library →

In animals1
In the lab0
Reviews1
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

Galinpepimut-S (GPS) vial rendering
Compound field notes

At a glance

Four things to know about Galinpepimut-S (GPS)

01

Evidence

Investigational

02

Category

Immune support

03

Common vial

Varies

04

Half-life

Not published

04

How much, and do you cycle it?

The range, and whether you take breaks.

800 mcg total, 200 mcg of each of the four peptides (published trials), six doses every two weeks, with monthly doses after (trial schedules). Six doses every two weeks, then monthly doses where the protocol allows Trial dose

The randomized protocols give six priming vaccinations at weeks 0, 2, 4, 6, 8 and 10 rather than open-ended treatment, with further monthly doses permitted for people whose disease has not progressed. It is given as maintenance during remission, so the schedule is set by the protocol rather than by anything a patient adjusts.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not publishedNo figure

No pharmacokinetic data have been published, and none would be expected to be informative. The peptides are deliberately held at the injection site by an oily emulsion so that antigen-presenting cells take them up locally rather than letting them circulate. The trials measure the immune response instead, as peptide-specific T cell responses, which in the phase 2 work rose several fold against each of the four peptides after six vaccinations.

You can compare this against the whole library to see where it sits.

06

How is it given?

Dosing context and source notes.
No draw available

Given in hospital from a prepared product, so there is nothing to mix.

Trial dose: 800 mcg per dose. Zauderer et al., A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma, Clinical Cancer Research 23(24):7483

Given by a nurse in a clinic, never self-administered. The published dose is 800 mcg of galinpepimut-S by total weight, which is 200 mcg of each of the four peptides in the mixture. The lyophilized powder is reconstituted with sterile water and then emulsified one to one with Montanide ISA 51 VG to a total volume of 1 mL, injected subcutaneously with the sites rotated among the limbs. Sargramostim, which is GM-CSF, is given separately at 70 mcg under the skin one to two days before and again on the day of each vaccination, and a patient may self-administer that component if trained. In the randomized mesothelioma trial the regimen was 70 mcg GM-CSF, 500 mcg Montanide and 800 mcg galinpepimut-S, with six vaccinations every 14 days at weeks 0, 2, 4, 6, 8 and 10; the myeloma protocol allowed up to six further monthly doses. The phase 3 trial's dose has not been separately published, and the 800 mcg figure is from the earlier randomized and registered protocols. There is no commercial presentation and no adjustment data, so the calculator has no dose to draw.

07

How do you store it?

Before mixing, and after.

Given in a hospital or trial clinic, so the pharmacy stores it.

Galinpepimut-S (GPS) is prepared and given by hospital, clinic or trial staff, following the product label or the trial protocol. Some products like this arrive ready to use and others are mixed just before the dose, often with hours rather than weeks of shelf life once prepared. It is not a medicine people store at home.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • Any use outside a clinical trial, because there is no approved product anywhere in the world
  • Treating it as a preventive vaccine, which it is not: every protocol gives it to people who already have the disease and are in remission
  • Expecting it to work alone, because no published protocol gives the peptides without both Montanide and GM-CSF

Stop and get help

These are emergencies. Seek care.
  • Any allergic reaction, meaning rash, swelling of the face or lips, or trouble breathing
  • An injection site reaction that ulcerates, spreads or does not settle
  • Fever with signs of infection, which in a leukemia population needs same-day assessment

Common effects

Expected, and usually mild.
  • Injection site reactions, described by the sponsor as the most common treatment-related effect and expected from the adjuvant.
  • Most treatment-related effects reported as mild to moderate in the phase 3, with no tables published.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

What has happened recently

Investigational everywhere, approved nowhere. It is licensed from Memorial Sloan Kettering Cancer Center, where it was discovered, and has been run through registered trials in acute myeloid leukemia, malignant pleural mesothelioma and multiple myeloma, as well as in combination with pembrolizumab in selected advanced cancers. The phase 3 REGAL trial reported in November 2026 that it met its primary overall survival endpoint, on topline company data with no publication, no confidence interval and no regulatory review of the full dataset. A biologics license application has been described as planned, but no application has been filed or accepted, and no agency anywhere has approved this product. This site's news page on the REGAL result sets out what the topline does and does not establish.

10

What else is like Galinpepimut-S (GPS)?

Others in Immune support, side by side.

If you're weighing Galinpepimut-S (GPS), it's worth reading Albuvirtide (Aikening), Evuzamitide (AT-01), and Thymalin in the same class.

Guides for this compound

Sources

  • Maslak, Scheinberg et al., Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia, Blood 116(2):171(2010)
    The originating phase 1 paper, read for the sequences and for the native comparators. Its vaccine formulation table lists WT1-A at RMFPNAPYL, residues 126 to 134, as the native peptide, and WT1-A1 at YMFPNAPYL over the same residues as the vaccine peptide, both 9 residues binding HLA-A0201. It lists 427 long at RSDELVRHHNMHQRNMTKL, residues 427 to 445, 19 residues; 331 long at PGCNKRYFKLSHLQMHSRKHTG, residues 331 to 352, 22 residues; 122A long at SGQARMFPNAPYLPSCLES as the native and 122A1 long at SGQAYMFPNAPYLPSCLES as the vaccine peptide, both residues 122 to 140, all binding HLA-DR.B1. The text states that the 122A1 long peptide is a CD4 epitope with a mutated amino acid R126Y and that the heteroclitic WT1-A1 sequence is embedded within the longer peptide. Immune responses were reported to each of the four peptides.
  • Zauderer et al., A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma, Clinical Cancer Research 23(24):7483(2017)
    The randomized phase 2 in mesothelioma, read for the dose and the schedule, which are the figures this page's dosing block rests on. Patients were randomized to receive GM-CSF 70 micrograms, Montanide 500 micrograms and galinpepimut-S 800 micrograms, stated as total weight, being 200 micrograms of each of the four peptides within the mixture, against the adjuvants alone. A series of six vaccines was given every 14 days at weeks 0, 2, 4, 6, 8 and 10, plus or minus 3 days. Each vial contained a final injectable dose of 200 micrograms of each peptide in a 0.5 mL vial with 40 percent overfill. The paper states that Montanide and GM-CSF were coadministered to retain the peptides at the injection site and induce local inflammation near the peptide.
  • Protocol and statistical analysis plan, NCT03761914, Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers(2019)
    A registered protocol, read via a reproduction because ClinicalTrials.gov could not be opened during this review, and cited for the composition statement and the administration detail. It describes galinpepimut-S as a lyophilized preparation of four different WT1-derived synthetic analog peptides considered as a multicomponent single drug product, with one peptide to stimulate CD8 responses, two long peptides to stimulate CD4 responses and one modified peptide able to stimulate both. It states that WT1-A1 and WT1-122A1 long contain a mutated residue, R126Y, and are therefore heteroclitic, and that the WT1-A1 sequence is embedded within the longer 122A1 peptide. It describes reconstitution of the lyophilized powder with sterile water followed by a one to one emulsion with Montanide ISA 51 VG to a total volume of 1 mL given subcutaneously, with sargramostim 70 micrograms subcutaneously on day minus 2 and on day 1 before each injection.
  • Memorial Sloan Kettering Cancer Center protocol IRB 12-288, WT-1 vaccine trial, supporting document to NCT01265433(2016)
    The originating institution's protocol, read via a reproduction for the manufacturing and administration detail. It names the manufacturer of the four peptides, lists the sequences WT1-A1 YMFPNAPYL, WT1-122A1 long SGQAYMFPNAPYLPSCLES and WT1-427 long RSDELVRHHNMHQRNMTKL, and states that the four peptides together with the immunological adjuvants Montanide and GM-CSF constitute the vaccine taken into human trials in acute myeloid leukemia and mesothelioma. It specifies that all injections are administered subcutaneously with sites rotated among extremities, that the 1.0 mL emulsion is administered by a nurse and may not be self-administered, and that patients may self-administer the GM-CSF component if appropriately instructed. HLA typing is recorded but a specific HLA type is not required for participation.
  • US9265816, Immunogenic WT-1 peptides and methods of use thereof(2016)
    The patent that introduced the heteroclitic long peptide, read for the design rationale behind the one-residue change. It describes generating a WT1 peptide spanning residues 122 to 140 with the sequence SGQARMFPNAPYLPSCLES, designated WT1 122, and then a peptide termed WT1 122A1 comprising the CD8 heteroclitic WT1A1 peptide YMFPNAPYL nestled inside the elongated CD4 epitope, with the sequence SGQAYMFPNAPYLPSCLES, and reports improved predicted binding across a broad array of HLA-DR types.
  • Targeted Oncology, Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML, November 18, 2026(2026)
    Independent oncology trade coverage of the phase 3 topline, read via a reproduction and cited for the headline result and the mechanism summary. Median overall survival was 24.0 months with galinpepimut-S against 14.7 months with best available treatment, hazard ratio 0.59, two-sided P equals 0.035, a 41 percent reduction in the risk of death, in transplant-ineligible patients with acute myeloid leukemia in second or later remission. The analysis was triggered by the prespecified 80th overall survival event. The coverage summarizes the mechanism as four WT1-derived peptides, modified short, native long and modified long, designed to broaden antigen-specific CD8 and CD4 T-cell immunity while preserving recognition of native WT1. This site's news page on the REGAL result covers the trial itself in detail.

Beyond these, 13 records are indexed for this compound. Browse the records